Nutriband Inc. (NASDAQ:NTRB - Free Report) - Noble Financial lowered their Q2 2026 earnings estimates for shares of Nutriband in a report issued on Monday, June 2nd. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.17) per share for the quarter, down from their prior forecast of ($0.16). The consensus estimate for Nutriband's current full-year earnings is ($0.60) per share.
Nutriband Price Performance
NASDAQ:NTRB traded up $0.44 during mid-day trading on Thursday, reaching $7.70. 27,019 shares of the company were exchanged, compared to its average volume of 80,747. Nutriband has a 12 month low of $3.72 and a 12 month high of $11.78. The company has a fifty day moving average of $5.77 and a 200 day moving average of $5.80. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The stock has a market cap of $85.89 million, a PE ratio of -10.84 and a beta of 1.11.
Nutriband (NASDAQ:NTRB - Get Free Report) last issued its quarterly earnings data on Friday, May 30th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.71 million.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in shares of Nutriband by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 62,435 shares of the company's stock valued at $294,000 after purchasing an additional 4,372 shares during the last quarter. Haven Private LLC acquired a new stake in shares of Nutriband in the 4th quarter valued at approximately $54,000. Finally, US Bancorp DE acquired a new stake in shares of Nutriband in the 1st quarter valued at approximately $29,000. Institutional investors own 19.70% of the company's stock.
Nutriband Company Profile
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Articles
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
